Published in Cancer Res on April 04, 2011
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
Understanding cancer stem cell heterogeneity and plasticity. Cell Res (2012) 2.39
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis (2012) 1.55
Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe (2014) 1.42
Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol (2012) 1.22
Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res (2012) 0.96
pIgR: frenemy of inflammation, EMT, and HCC progression. J Natl Cancer Inst (2011) 0.88
Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol (2016) 0.88
C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget (2016) 0.87
Turning hepatic cancer stem cells inside out--a deeper understanding through multiple perspectives. Mol Cells (2015) 0.86
Cellular reprogramming and hepatocellular carcinoma development. World J Gastroenterol (2013) 0.86
Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma. Biomed Res Int (2014) 0.83
Shared mechanisms in stemness and carcinogenesis: lessons from oncogenic viruses. Front Cell Infect Microbiol (2013) 0.83
Oncogenes and RNA splicing of human tumor viruses. Emerg Microbes Infect (2014) 0.82
Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma. Springerplus (2014) 0.81
Hepatocellular carcinoma: from hepatocyte to liver cancer stem cell. Front Physiol (2015) 0.79
Nanog and β-catenin: a new convergence point in EpSC proliferation and differentiation. Int J Mol Med (2011) 0.78
Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells. Oncotarget (2016) 0.76
Transarterial Therapies for Hepatocellular Carcinoma. Liver Cancer (2016) 0.75
Progressive Enrichment of Stemness Features and Tumor Stromal Alterations in Multistep Hepatocarcinogenesis. PLoS One (2017) 0.75
Cytoplasmic EpCAM over-expression is associated with favorable clinical outcomes in pancreatic cancer patients with Hepatitis B virus negative infection. Int J Clin Exp Med (2015) 0.75
The Role of HPV in Head and Neck Cancer Stem Cell Formation and Tumorigenesis. Cancers (Basel) (2016) 0.75
C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. Oncotarget (2017) 0.75
Evidence of Hepatitis B Virus Infection in Cancer and Noncancer Stem Cells Associated with Human Hepatocellular Carcinoma. Can J Infect Dis Med Microbiol (2016) 0.75
Adult hepatic cavernous hemangioma with highly elevated α-fetoprotein: A case report and review of the literature. Oncol Lett (2014) 0.75
Hepatitis B virus X protein promotes the stem-like properties of OV6(+) cancer cells in hepatocellular carcinoma. Cell Death Dis (2017) 0.75
Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization. Mod Pathol (2016) 0.75
The evolving concept of liver cancer stem cells. Mol Cancer (2017) 0.75
USP16 Downregulation by Carboxyl-terminal Truncated HBx Promotes the Growth of Hepatocellular Carcinoma Cells. Sci Rep (2016) 0.75
Hepatitis B virus X protein in liver tumor microenvironment. Tumour Biol (2016) 0.75
Hepatitis B virus X protein-induced upregulation of CAT-1 stimulates proliferation and inhibits apoptosis in hepatocellular carcinoma cells. Oncotarget (2017) 0.75
β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study. Virchows Arch (2015) 0.75
Cadherin cell adhesion receptors as a morphogenetic regulator. Science (1991) 13.78
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A (1999) 10.75
Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell (2005) 9.84
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
How is pluripotency determined and maintained? Development (2007) 6.92
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
The role of epithelial-mesenchymal transition in cancer pathology. Pathology (2007) 5.16
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89
The oncogenic activation of beta-catenin. Curr Opin Genet Dev (1999) 3.87
The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res (2009) 3.25
Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A (2008) 2.98
Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer (2005) 2.84
Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res (2007) 2.63
Repression of Nanog gene transcription by Tcf3 limits embryonic stem cell self-renewal. Mol Cell Biol (2006) 2.63
The phenotypes of pluripotent human hepatic progenitors. Stem Cells (2006) 2.41
Human embryonic genes re-expressed in cancer cells. Oncogene (2001) 2.26
Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol (1997) 1.95
Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol (2008) 1.95
Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem (1999) 1.75
Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol (1996) 1.62
Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology (2004) 1.57
Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol (2007) 1.56
Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J Biol Chem (2010) 1.52
Hepatocellular carcinoma. Curr Opin Gastroenterol (2006) 1.50
Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med (1990) 1.40
Wnt signaling in liver cancer. Curr Drug Targets (2008) 1.34
Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res (1991) 1.25
E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma. Hepatology (1996) 1.24
Trans-activation function of a 3' truncated X gene-cell fusion product from integrated hepatitis B virus DNA in chronic hepatitis tissues. Proc Natl Acad Sci U S A (1990) 1.20
Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene (2006) 1.15
Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells (2007) 1.14
Hepatitis B virus in hepatocarcinogenesis. J Cell Physiol (1999) 1.14
Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling. Cancer Lett (2010) 1.07
Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. J Viral Hepat (1996) 1.07
Presence of antibodies to the polymerase gene product(s) of hepatitis B and woodchuck hepatitis virus in natural and experimental infections. J Med Virol (1988) 1.03
Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis (2010) 1.02
The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene (1999) 1.02
The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene (2001) 1.00
Hepatitis B X-gene expression in hepatocellular carcinoma. J Hepatol (1992) 1.00
Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology (2006) 0.99
microRNAs, RNA binding proteins and cancer. Eur J Clin Invest (2010) 0.97
Truncated form of beta-catenin and reduced expression of wild-type catenins feature HepG2 human liver cancer cells. Ann N Y Acad Sci (1999) 0.95
Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses. Carcinogenesis (2008) 0.94
Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription. Virus Res (2008) 0.91
Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
Genetic mechanisms of hepatocarcinogenesis. Oncogene (2002) 2.21
Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics (2006) 1.65
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg (2007) 1.63
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut (2011) 1.56
Molecular pathogenesis of hepatocellular carcinoma. Liver Int (2007) 1.50
Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol (2010) 1.40
Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology (2006) 1.33
Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One (2012) 1.15
C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology (2013) 1.15
Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b. Liver Int (2015) 1.11
Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol (2010) 1.10
Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother (2013) 1.08
Early molecular and genetic determinants of primary liver malignancy. Surg Clin North Am (2004) 1.08
Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia (2002) 1.06
PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene (2004) 1.05
Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res (2002) 1.04
Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett (2002) 1.04
Enhanced cell survival of gastric cancer cells by a novel gene URG4. Neoplasia (2006) 1.03
Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology (2006) 0.99
Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res (2002) 0.98
The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint. Exp Cell Res (2004) 0.97
Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res (2012) 0.96
The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation. Mol Cell Biol (2011) 0.94
Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses. Carcinogenesis (2008) 0.94
Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm). J Proteome Res (2010) 0.93
Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res (2004) 0.93
Osteomyelitis with proliferative periostitis: an unusual case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2006) 0.92
Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. Int J Cancer (2008) 0.92
Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim Biophys Acta (2010) 0.91
Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver (2002) 0.89
URG11 promotes gastric cancer growth and invasion by activation of beta-catenin signalling pathway. J Cell Mol Med (2008) 0.89
Hepatitis B virus X protein mutants exhibit distinct biological activities in hepatoma Huh7 cells. Biochem Biophys Res Commun (2008) 0.89
Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology (2007) 0.89
Human S15a expression is upregulated by hepatitis B virus X protein. Mol Carcinog (2004) 0.88
Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis. J Cell Physiol (2004) 0.87
Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Mol Carcinog (2009) 0.87
Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. Int J Cancer (2009) 0.87
Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer (2009) 0.86
Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease. Cancer Lett (2009) 0.86
The expression of novel gene URG4 in osteosarcoma: correlation with patients' prognosis. Pathology (2009) 0.85
Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin. J Gen Virol (2004) 0.84
Hepatitic graft-versus-host disease after hematopoietic stem cell transplantation: clinicopathologic features and prognostic implication. Transplantation (2004) 0.84
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin. J Gen Virol (2007) 0.83
PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. Pathol Oncol Res (2009) 0.83
UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines. BMC Cancer (2013) 0.83
Identification and characterization of tropomyosin 3 associated with granulin-epithelin precursor in human hepatocellular carcinoma. PLoS One (2012) 0.82
Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenesis. Front Biosci (2005) 0.81
The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol (2013) 0.81
Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment. Life Sci (2002) 0.81
Allelic alterations in nontumorous liver tissues and corresponding hepatocellular carcinomas from chinese patients. Hum Pathol (2003) 0.81
Development of a novel mouse model to evaluate drug candidates against hepatitis B virus. Antivir Chem Chemother (2007) 0.80
Adenoviral-mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma. Int J Cancer (2010) 0.80
Preparation and characterization of a specific monoclonal antibody against a new gene product: URG11. Hybridoma (Larchmt) (2006) 0.79
Transient inhibition of Th1-type cytokine production by CD4 T cells in hepatitis B core antigen immunized mice is mediated by regulatory T cells. Immunology (2006) 0.79
Upregulated expression of a unique gene by hepatitis B x antigen promotes hepatocellular growth and tumorigenesis. Neoplasia (2003) 0.79
Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrob Agents Chemother (2012) 0.78
Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein. Liver Transpl (2011) 0.78
A spiroligomer α-helix mimic that binds HDM2, penetrates human cells and stabilizes HDM2 in cell culture. PLoS One (2012) 0.78
Galactosamine-induced fulminant liver failure--observation in a porcine model. Asian J Surg (2002) 0.78
Different response requirements for IFNgamma production in ELISPOT assays by CD4+ T cells from mice early and late after immunization. J Immunol Methods (2005) 0.77
c-myc overexpression in hepatocarcinogenesis. Hum Pathol (2004) 0.77
Down-regulation of retinol binding protein 5 is associated with aggressive tumor features in hepatocellular carcinoma. J Cancer Res Clin Oncol (2007) 0.77
Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomark (2012) 0.77
The role of pathology and pathologists in the detection and management of cancer. Hong Kong Med J (2007) 0.75
Detection of hepatitis B virus X antigen by immunohistochemistry and Western blotting. Methods Mol Med (2004) 0.75
Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma. Expert Opin Pharmacother (2008) 0.75
[Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma and their significance in clinical settings]. Zhonghua Gan Zang Bing Za Zhi (2007) 0.75
Fatal skin rashes and myalgia in a leukaemic patient. Haematologica (2003) 0.75
Role of liver biopsy in the management of liver dysfunction after hematopoietic stem-cell transplantation in a hepatitis B virus-prevalent patient population. Transplantation (2003) 0.75
Protein-losing enteropathy due to T-cell large granular lymphocyte leukemia. J Clin Oncol (2009) 0.75